UK markets closed

Bausch Health Companies Inc. (BHC)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
27.59+0.06 (+0.22%)
As of 1:09PM EDT. Market open.
Sign in to post a message.
  • a
    anthony
    "It ain't over till it's over." Yogi Berra. If you don't want to be in this stock, then sell it and stop complaining. I think a lot of us are holding out with the big money that's came into the stock and will see what happens.
  • F
    Fred
    Physicians (Why were physicians so very wrong about Provenge for so long?):
    1: Oct 2012: "Data from the IMPACT trial, as reported in the NEJM, showed that patients who received Provenge lived 4.1 months longer on average than men who received the placebo treatment. That benefit has been seized upon by doctors considering whether to prescribe the $93,000 therapy and by men deciding whether to undergo it."?

    2: Spring 2019: " “It was a little labor-intensive to give the drug and, for all of this, the return seemed like it was very little,” she said. “Patients would say, ‘I go through all of this, did it really work?’ We physicians had to put up our arms and say, ‘We have no idea.’ We know the PSA doesn’t go down. Eventually people live longer, and patients ask by how much, and we say four months. But patients themselves are not that impressed.”"?

    But, But, But

    3: July 2020: "Nearly 4 Year Median OS in Men with Low PSA"?

    Hmmm
  • J
    Jeffrey
    BHC has a current Market Cap of LESS THAN $9 Billion .
    BHC paid $9 Billion for Bausch & Lomb 8 years ago. Markets are putting a Negative Value on everything other than B&L.
    WW was $20 just 3 trading days ago. WW is now $39 just trading days later.
  • G
    G
    b+l if it were to trade at 15x EBITDA, would equate to 30billion market cap...this is the high end of the range Bloomberg reported it being worth in a sale. in that scenario, the rest of the company with 1.6b to1.8b EBITDA, is currently worth...0$
  • D
    Dan
    Analyst Douglas Miehm from RBC Capital maintained a Buy rating on Bausch Health Companies (BHC), with a $41 price target.
  • F
    Fred
    1: Oct 2012: "Data from the IMPACT trial, as reported in the NEJM, showed that patients who received Provenge lived 4.1 months longer on average than men who received the placebo treatment. That benefit has been seized upon by doctors considering whether to prescribe the $93,000 therapy and by men deciding whether to undergo it."?

    2: Aug 2012: Zytiga prolonged median survival by 3.9 months, as initially reported, though Johnson & Johnson later updated that figure to 4.6 months."?

    3: Nov 2014: "Dendreon Files for Bankruptcy as Cancer Drug Disappoints"?

    4: Jan 2019: "Zytiga is still romping away, with a 40% gain in the year to $3.5 billion "?

    But, But, But

    5: Aug 2020: "Urologists and others treating prostate cancer are living in a prostate cancer “revolution”. Five to seven years ago, it didn’t seem possible that men with mCRPC could live two years after their diagnosis, and now real-world data is showing us it may be as long as four years or longer if immunotherapy is used when PSA levels are lower and likely to offer the most benefit."?

    6: Feb 2021: "Booming indeed! We're proud of the nearly 200 teammates that keep our Union City immunotherapy manufacturing facility running so we can serve patients."?

    DNDN shareholders were Grossly Cheated. IMO
    What is Dendreon really worth today? How many Billions of Dollars?
  • F
    Fred
    1: Mar 2012: "Despite the heated rhetoric, Provenge may go out with a whimper more than a bang. Promising new agents for advanced prostate cancer include an oral drug from Medivation Inc called enzalutamide, in the final phase of clinical trials, and Zytiga from Johnson & Johnson, which won FDA approval in 2011. A vaccine that targets PSA, from Bavarian Nordic Immunotherapy, is in late-stage trials."?

    2: Aug 2012: Zytiga prolonged median survival by 3.9 months, as initially reported, though Johnson & Johnson later updated that figure to 4.6 months."?

    3: Nov 2014: "Dendreon Files for Bankruptcy as Cancer Drug Disappoints"?

    4: Jan 2019: "Zytiga is still romping away, with a 40% gain in the year to $3.5 billion "?

    But, But, But

    5: Aug 2020: "Urologists and others treating prostate cancer are living in a prostate cancer “revolution”. Five to seven years ago, it didn’t seem possible that men with mCRPC could live two years after their diagnosis, and now real-world data is showing us it may be as long as four years or longer if immunotherapy is used when PSA levels are lower and likely to offer the most benefit."?

    6: Feb 2021: "Booming indeed! We're proud of the nearly 200 teammates that keep our Union City immunotherapy manufacturing facility running so we can serve patients."?

    DNDN shareholders were Grossly Cheated. IMO
  • j
    jan
    Another Day in red Down more than 50 cent , but Dow up 250 ??
    Same case every Day
    What would happen if Dow was in red
  • M
    Mar
    Just an initial thought. More to follow as time permits.

    Given the Good will impairments of 469 Million relating to the Ortho Dermatologics Segment being booked and given the Fruedian slip by 'buddy' dring the conference call, Ortho Dermatalogics is being, "quite quickly" sold.
    For those of you exiting, have a nice trip; just don't look back. As soon as you, the retail shareholders are done dumping your positions and such positions are accumulated by intermediaries on behalf of the purchaser of the Ortho Dermatological bussiness segment and/or other most interested parties; that is when the 469 Million of good will impairment will fade to the back of your mind and be replaced at the forefront of your mind with the realization that you missed yet another opportunity to ride the share price up from the very depths at which it is to be taken to by our 'friend' the market maker (s) and all those intermediaries operating on behalf of the 'institutional' owners of BHC - of which there are an overwhelming majority .
    You, the retail shareholder are, by design, being told to exit stage left whilst a consolidation of your respective positions is underway, as evidenced by the engineered share price reaction taking place today.
  • M
    Mar
    ... continued.
    Well, who would't want to own BHC shares at that point?
    After all, without the ownership of existing common shares before the cut off date, there would be no way to participate in the parabolic upward swing in share price as a result of the entirety of the B&L eyecare business segment, entirely absent any attached debt, being spun off and then becoming the very focus of a takeover attempt, at the market, the very day of it's Initial Public Offering or at some point immediately thereafter... ***
    Simply, if you have to ask why, you may have been living under a rock, had your head stuck in the sand, been living on some other planet perhaps, lol, or are simply not that well versed in how 'moonshots' or 'parabolic' common share price moves are engineered; and in a comprehensively considerate and entirely legal manner.
  • b
    bz
    Just a quick thought having time to digest the financial breakdown Management provided by business segment and their proposed capital structure associated with BHC Pharma and B&L. The spin-off will not take place under the proposed structure. I will not bore you with the detail and there are many but I would refer you to their multiple senior debt facility and covenants. The proposed structure for BHC Pharma does not fit within 70% of the parameters defined by the coverages not to mention the lenders will not give up the cross collateral between bhc and b&l and assume the associated risk. I am bullish BHC and all her segments. It could be a sale is n the works, going private many options but the spin-off will not take place. The volatility in price last several days is not assessment of risk but of time value for those who thought there was a defined monetization 3rd qtr - the one defined will not take place, this extends duration under most scenarios that are public. Good luck to all longs.
  • G
    God Bless America
    Big companies have done successful spinoffs before. A couple of them I owned: HP and Alcoa. I ended up selling the original stock and the spinoff and made a return of more than 50%. If Bausch wants to spinoff their "bread and butter" line of business, the new company will do extremely well. Eventually, they will be able to focus more on the other lines of business and potentially either sell it all (stock and barrel) or in pieces. I feel optimistic.
  • M
    Mar
    57 minutes ago

    What's that you said? Did you say you want me to issue a news release.
    Wake up! The Ortho Dermatologics segment is sold. Cha ching! There's another $700 Million or so, coupled with the already booked good will impairment and resultant accumulated tax attribute.

    What's that again? Did you say you wanted me to warn those presently short BHC.

    Hear ye, Hear ye! 'Quickly' cover your short positions and go long BHC shares and BHC call options. You'll be able to more than double your expected return and certainly won't get caught up in the expected engineered short squeeze.

    What's that you say. Corporate debt retirement can happen 'very quickly' and due to recent approaches and offers tabled relating to a great majority of the company's debt, the timeline for the Bausch & Lomb IPO is now slated to occur much sooner than October of 2021.
  • M
    Mar
    Did you say you have 6 months to buy BHC shares in order to get the benefit of the spin off of B&L eyecare?
    LOL! You obviously didn't listen to the conference call in it's entirety, G.
    When I tell you that your head is going to spin once the action gets going Action, such as massive debt retirement, is going to take place "quite quickly" - as the CFO stated and then talked back; saying it could happen a greater pace or something to that effect. the Ortho segment is as good as gone; and by the time you figure it out, there won't be more than two segments left to BHC.
    We won't have to wait until October; not at all.
  • M
    Mar
    Security Issue Name Security Symbol Exchange Code No.Shares Net Change

    BAUSCH HEALTH COMPANIES INC. BHC TSX 2186595 -244816

    Other than perhaps someone somehow possessing some pejorative inside information which could prove to be be quite destructive to the current share price, who would elect to maintain a BHC short position going into this evening, the evening before the morning during which BHC's quarterly results are to be released premarket.
    To reiterate, as corporate diclosure and public dissemination guidelines would indicate, Mr. Papa could concurently provide quarterly results and during the premarket conference call also provide BHC shareholders and "the street' with a confirmation of proposed offers for the purchase of the B&L eyecare business segment and/or other material assets of the corporation. Although unlikely, Mr. Papa and Co. could very well provide 'the street' with some abosute clarity in terms of precisely what price any proposed purchaser is willing to pay for the company's assets, either in part or in whole.
    What would most certainly happen to the position of any persons who elected to maintain their respective BHC short positions leading into the open?
    Can you say short SQUEEZE?
  • M
    Michael
    The major BHC shareholders had to have foreseen this happening. They must have the deepest insights into the companies revenues and projected sales. Carl Icahn and company must also realize that at some point COVID will be gone. Life will return to normal. People will start wearing contact lenses to the office and when going out with friends. When folks start returning to the office, an unfortunate side-effect is that chronic stress will return which of course results in digestive issues that greatly affect the Salix bottom line. If we can get COVID under control, the next quarter may be an inflection point for BHC.
  • j
    jan
    Does anyone have inside news for tomorrow ?, why Down today
  • M
    Mar
    What follows are just a couple of basic questions which should be answered by Mr. Papa et al. during the earnings release premarket conference call or sooner.

    1 - Are there any proposals put forth by the company which BHC stakeholders and holders of senior secured debt issuances are collectively considering, this in relation to somehow converting a quite sizable amount of presently issued senior secured debt into common shares of the corporation; if so, how would doing so specifically impact the company financially in order to facilitate such a conversion of said debt and would doing so be in any way preferable?

    2 -What exactly are the various proceedes from the sale of the Amoun businees segment going to be predominantly utilized for and how, if at all, will such funds be utilized in some specific fashion to finally address sizably lowering the pertinent debt ratio, thus taking the company that much closer to spinning out, in part or in whole, the B&L eyecare segment; or, is the spin out of the B&L eyecare business segment no longer the most viable option in order to produce greater BHC shareholder appreciation?

    3 - Would you tell us whether there have been, as reported by an affiliate of Bloomberg news media, new developments as pertain to apparently very generous proposals to outright purchase the B&L eyecare segment, making a previously proposed public spin out of B&L less likely now?

    4 - You do appreciate that with all the built up anticipation of a previously promoted Initial Public Offering of the B&L eyecare business segment and given the resultant marked appreciation in the company's share value since announcing the specific intention to spin out the B&L segment, there could be a marked negative backlash experienced by BHC shareholders; this, should you decide to abandon the previously stated intention to monetize part or all of the company's ownership of the Bausch & Lomb eyecare division and not concurrently provide common shareholders with a more profitable avenue in replacement of the previously stated intention. Given this, would you be prepared to provide BHC shareholders with a comprehensive discussion of determinant factors already arrived at in support of exactly how you plan on executing the highly touted Initial Public offering of the B&L eyecare business segment?

    5 - What, if anything at all, has Carl Icahn's appointed representative to the company's board of directors proposed to help faciliate the production of as yet untapped BHC shareholder value and has said representative extended any kind of bonafide offer on the part of his father and/or associated principals, in relation to the B&L eyecare business segment or any of the other material assets of the cororation?
  • A
    Albert
    For the record, I highly doubt that BHC's Credit Agreement and respective Prospectuses bar them from paying down debt (BHC has been retiring debt consistently for ages).

    ALSO, I never stated that BHC would sell the Company to pay down debt. That reflects a lack of reading comprehension.

    BHC will generate $3.6B in EBITDA this year and am actually expecting $3.8B during 2021. Approximately $2.0B of that arises from Bausch. BHC could sell Bausch to KKR at a 12x-to-15x multiple, retire 100% of the debt and leave legacy shareholders with the remaining assets ($1.8B of EBITDA, the psoriasis treatment and a few other magnificent 7 drugs). Assuming 12x EBITDA on the remaining assets and zero net debt reflects a large profit to existing shareholders.

    SOME of what the poster said is accurate, and his stance on cross-collateralization is fairly accurate, but remain skeptical whenever someone "guarantees" something (especially when the opinion is a "run-on" sentence).
  • B
    Bond
    BHC are now worth $40 to $55 per share after it unload eyes care business.